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Abstract
PURPOSE—Young individuals with occlusive, proximal limb DVT who have acutely elevated
plasma levels of factor VIII and D-dimer are at high risk for post-thrombotic syndrome (PTS)
when treated with conventional anticoagulation alone. We sought to evaluate our experience with
adjunctive percutaneous mechanical/pharmacomechanical thrombolysis (PMT/PPMT) in such
patients.
PATIENTS AND METHODS—Among 95 children 11 to 21 years of age enrolled in a
prospective cohort of venous thromboembolism between March 1, 2006 and November 1, 2009,
16 met eligibility criteria and underwent PMT/PPMT, typically with adjunctive catheter-directed
thrombolytic infusion (CDTI) of tissue-type plasminogen activator given post-procedure.
RESULTS—Median age was 16 years (range: 11–19 years). Thirteen cases (81%) involved lower
limbs. Underlying stenotic lesions were disclosed in 53%, with endovascular stents deployed in all
cases of May-Thurner. There were no peri-procedural major bleeding events and one symptomatic
pulmonary embolism. Technical success rate was 94%. Early (<30 days) locally recurrent DVT
developed in 40%, of which 83% were successfully re-lysed. Late recurrent DVT rate (median
follow-up duration: 14 months [range: 1–42 months]) was 27%. Cumulative incidence of
physically and functionally significant PTS at 1–2 years was 13%.
CONCLUSION—This experience provides prospective evidence that PMT/PPMT with
adjunctive CDTI can be used safely and effectively in adolescents with DVT at high risk for PTS.
Correspondence: Dr. Neil A. Goldenberg, Mountain States Regional Hemophilia and Thrombosis Center, Univ. of Colorado, P.O. Box
6507, Aurora, CO 80045, neil.goldenberg@ucdenver.edu.
Conflicts of interest: None.
NIH Public Access
Author Manuscript
J Vasc Interv Radiol. Author manuscript; available in PMC 2012 February 1.
Published in final edited form as:














Current consensus-based recommendations for antithrombotic therapy of deep venous
thrombosis (DVT) in children suggest that thrombolytic interventions be reserved for
patients with life- or limb-threatening events [1]. However, a risk of post-thrombotic
syndrome (PTS) of nearly 80% was recently determined in a small cohort study evaluating a
subgroup of young patients with DVT—defined by completely veno-occlusive proximal
lower limb DVT in association with acutely elevated plasma levels of factor VIII and D-
dimer—managed by conventional anticoagulation according to the present standard of care
[2]. This study further observed that when thrombolysis (typically consisting of systemic
tissue-type plasminogen activator [tPA] by low-dose continuous intravenous infusion, with
salvage percuatenous mechanical or pharmacomechanical thrombolytic [PMT/PPMT]
intervention for persistent occlusion) was employed prior to conventional anticoagulation,
the risk of PTS was significantly reduced (OR=0.02, 95% confidence interval=<0.001–
0.48), at 22%. This PTS rate is similar to the historical frequency of PTS recently defined in
largely unselected children with a history of upper or lower extremity DVT by systematic
review [3].
Present recommendations for antithrombotic management of DVT in adults suggest that
thrombolysis be considered in young patients with a long anticipated lifespan who have a
low bleeding risk and extensive and/or occlusive thrombus of recent symptomatic onset [4].
Since most children with PTS are anticipated to endure the associated symptoms and signs
for a lifetime that spans many decades, it is imperative that risk-stratified antithrombotic
therapeutic strategies be developed and prospectively studied in the pediatric population,
with PTS risk reduction as a key aim. Principal among these strategies is the rapid
restoration of venous patency via thrombolysis. To date, the few studies of thrombolysis in
pediatric venous thromboembolism (VTE) have focused upon modalities of either systemic
or catheter-directed thrombolytic infusion (CDTI), including tPA most recently and
urokinase in the recent past [2,5,6]. However, a recent survey identified PMT/PPMT as the
most commonly preferred approach to thrombolysis in pediatric DVT among physician
members of the American Society of Pediatric Hematology/Oncology [7], even in the
absence of any published experience apart from a few small retrospective case series.
Accordingly, we sought to evaluate our institutional prospective cohort study experience
with PMT/PPMT in adolescents with acute proximal limb DVT who were judged to be at




Consecutive children evaluated for VTE at The Children’s Hospital, Colorado and the
Mountain States Regional Hemophilia and Thrombosis Center at the University of Colorado
Denver were approached for enrollment in an institution-based prospective inception cohort
study of pediatric VTE between March 1, 2006 and November 1, 2009 (Colorado Multiple
Institutional Review Board approval #05–0339). Informed consent was provided in
accordance with the Declaration of Helsinki. Study inclusion criteria for the present analysis
consisted of: (1) Age ≥11 and ≤21 years at presentation; (2) symptomatic, completely veno-
occlusive DVT of a proximal limb, objectively confirmed via appropriate radiologic
imaging studies (compression ultrasound with Doppler, computed tomography with
venography [CTV], magnetic resonance imaging with venography [MRV], conventional
venography); (3) plasma factor VIII activity and D-dimer concentration above prognostic
thresholds (150 U/dL and 0.5 µg/mL, respectively) upon initial testing within two weeks
following DVT confirmation; (4) PMT/PPMT via an interventional radiologic approach; (5)
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prospective follow-up in the Pediatric Thrombosis Program at the University of Colorado
Denver and The Children’s Hospital, Colorado; (6) signed informed consent/assent for study
participation. The only exclusion beyond these eligibility criteria was a lag to PMT/PPMT
of ≥ 60 days from time of symptom onset. Figure 1 provides a flow chart of study
population eligibility.
PMT/PPMT regimens
Patients were carefully evaluated for contraindications to local thrombolysis (Figure 2); no
children required exclusion for contraindications. In addition to informed research consent
for cohort study participation, informed procedural consent was obtained in all cases. A
clinical protocol was employed for each component of the PMT/PPMT intervention (Figure
3), which permitted variability in the number of modalities utilized, based upon clinical
discretion. In brief, baseline venography was performed to establish anatomy, thrombus
burden, and degree of occlusion. Using realtime ultrasound guidance, a 21-gauge needle was
introduced into the popliteal vein for lower limb DVT or the basilic veins for upper limb
DVT. In the setting of thrombus within one of these two venous systems, puncture was
made peripheral to the thrombosed vein and an attempt at passing a wire through the
thrombus was made. Via standard wire and catheter exchanges, a hydrophilic wire was
advanced through the thrombus to its proximal (central) terminus and a central venogram
was obtained. An appropriately-sized sheath was then placed over the guidewire.
One of three mechanical thrombectomy devices (AngioJet® [MEDRAD Interventional/
Possis, Inc., Warrendale, PA, USA]; Amplatz ClotBuster® Thrombectomy Device [ev3 Inc.,
Plymouth, MN, USA]; or Trellis® [Bacchus Vascular, Inc., Santa Clara, CA, USA]),
ranging in caliber from 5–8 F, was advanced through the sheath. Mechanical thrombectomy
was performed according to manufacturer specification, in serial passes as necessary/
possible to achieve maximal patency and minimal residual clot burden. When local tPA was
administered via the device during MT (i.e.: Trellis®; some cases of ClotBuster® or
Angiojet®), this was characterized as PMT. At the discretion of the operator (or in all cases
of May-Thurner anomaly), additional percutaneous transluminal angioplasty was performed
and one or more 12–16 mm stents (WALLSTENT®, Boston Scientific, Natick, MA, USA)
were deployed at sites of residual stenosis. If thrombus was noted to extend peripheral to the
popliteal vein (i.e. including calf veins), no attempt was made to lyse this portion of the
thrombus. No duplicate venous systems were identified during this study.
In most cases, catheter-directed thrombolytic infusion (CDTI) was administered post-
procedure directly into residual thrombus, for a period of 12–24 hours. CDTI uniformly
employed tPA at 0.5–1 mg/hr via an infusion catheter placed in the sheath and directed at
the site of PMT/PPMT or residual thrombus. During CDTI, unfractionated heparin was
given at 10 U/kg/hr via the sheath (except in cases in which a diagnosis of severe
thrombophilia [e.g., homozygous protein S deficiency] or thrombotic storm [8] was made,
wherein more aggressive antithrombotic therapy was maintained [Table 3]).
Complete blood count, prothrombin time, activated partial thromboplastin time, fibrinogen
activity (Clauss method), plasminogen activity, and D-dimer concentration were measured
every 12 hours during, and for 24 hours after, the thrombolytic regimen. In the absence of
bleeding concerns, therapeutic anticoagulation was transitioned to low molecular weight
heparin (LMWH) 24-hours post-procedure, monitored by anti-Xa activity (goal: 0.5–1.0
anti-Xa U/mL). Anticoagulation was maintained with LMWH or warfarin (goal INR: 2.0–
3.0) for a minimum total duration of six months, and not less than three months from the
time of any stent placement. Duration of anticoagulation was guided by American College
of Chest Physicians consensus-based recommendations [1].
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Systematic, prospective collection of clinically-derived data included: patient demographics;
timing of symptom onset; thrombus site, extent and degree of occlusion; clinical risk factors
for DVT; thrombophilia findings; presence of May-Thurner anomaly or Paget-Schroetter
syndrome; interventions and medical regimens employed, and timing thereof; peri-
procedural (≤7 days) major bleeding complications; peri-procedural pulmonary embolism
(PE); technical success (end-of-intervention); rethrombosis (i.e., locally recurrent DVT); all
recurrent VTE (all sites); and PTS. Major hemorrhage was defined as bleeding involving or
resulting in any one of the following: central nervous system; retroperitoneum; decline in
hemoglobin of ≥2 g/dL in a 24 hour period; need for invasive procedure to achieve
hemostasis; death. In accordance with previously established reporting standards, technical
success was characterized by grade II/III (>50%) lysis, early locally recurrent DVT was
defined as that which was objectively confirmed within 30 days post-intervention, and late
recurrent DVT as greater than 30 days post-procedure [9].
Based upon institutionally-defined standard/best clinical care, all children underwent
comprehensive thrombophilia testing as adapted from International Society of Thrombosis
and Haemostasis recommendations [10] as previously described [11], in order to define risk
factors for DVT onset and/or its recurrence. Severe deficiencies of coagulation regulatory
proteins were defined as antithrombin <30 U/dL and protein C or protein S <20 U/dL),
while mild deficiencies were defined as antithrombin 30–60 U/dL and protein C or S 20–40
U/dL. These deficiencies were further distinguished as inherited versus acquired based upon
persistence versus non-persistence of the abnormality upon follow-up assessment 12 weeks
or more from the time of initial testing, with supportive evidence provided via testing of
family members.
Radiologic imaging surveillance was performed in order to exclude thrombus progression/
recurrence on therapy as well as to define the extent of chronic thrombus burden of any
residual thrombus. Specifically, imaging was repeated at end of PMT intervention, 1–4
weeks, 3–6 months, and (if persistent) at 1 year. Additionally, children were evaluated for
PTS using the Manco-Johnson instrument at 3–6 months, 1 year, and annually thereafter in
long-term follow-up. As reported previously [12], the Manco-Johnson instrument consists of
a physical exam component (basic CEAP [13]) as well as a functional component
(assessment of chronic pain with age-appropriate aerobic activities, activities of daily living,
and at rest, using the Wong-Baker scale [14]). Validation data have been published for the
use of the Manco-Johnson instrument in pediatric PTS assessment following DVT of the
lower limbs [2], and have likewise been recently presented for non-catheter-related DVT of
the upper limbs [15].
Statistical methods
Descriptive statistics were employed to define distributions of continuous data and
frequencies/proportions of categorical data. Ninety-five percent confidence intervals (95%
CI) were calculated using the Wald method. Cumulative incidence of PTS (expressed as a
proportion) was calculated based upon findings at 1–2 years post-diagnosis; findings from
the 2-year evaluation were used for this analysis, when available.
In the hypothesis tests, distributions and proportions were compared between groups of
interest via Mann-Whitney U and chi-square testing, respectively, with Fisher’s exact test
used for circumstances in which frequency values were ≤5 in a 2-by-2 table. An alpha of
0.05 was considered statistically significant. All hypothesis tests were two-sided, and were
performed using SAS 9.1 statistical software (SAS Institute, Cary, NC).
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Among 91 children aged 11–21 (inclusive) with VTE who enrolled in an institution-based
prospective cohort study between March 1, 2006 and November 1, 2009, 19 had completely-
occlusive proximal limb DVT in association with acute elevation of FVIII and D-dimer
(Figure 1). Of these, 16 (18% of enrolled subjects with VTE) elected to undergo PMT/
PPMT as part of clinical care within 60 days of symptom onset, after consideration of risks
and benefits of treatment options. These 16 adolescents comprise the study population for
the present analysis. Demographics, baseline patient and thrombus characteristics, and DVT
risk factors in the study population are presented in Table 1.
Median age was 16 years (range: 11–19 years). Thirteen cases (81%) were lower limb DVT,
nearly all of which involved the iliofemoral circulation. Four lower limb DVT cases (31%)
involved the inferior vena cava (IVC). Underlying stenotic venous anomalies (specifically,
May-Thurner anomaly or Paget-Schroetter syndrome) were definitively diagnosed in eight
(53%) of 15 evaluable subjects (in subject #16, the thrombus was too organized to allow
passage of a guidewire, and definitive diagnosis of Paget-Schroetter syndrome was therefore
not possible due to subclavian involvement with residual occlusive thrombus). Endovascular
stents were deployed in all cases of May-Thurner anomaly.
Treatment
Antithrombotic treatments, including thrombolytic interventions, are shown in Table 2 Five
patients received low-dose systemic tPA (0.03–0.06 mg/kg/hr) by continuous intravenous
infusion for 48–96 hrs prior to PMT/PPMT; in these cases, PMT/PPMT was initiated due to
persistent veno-occlusion. PMT/PPMT was successfully conducted in 15 cases; CDTI was
employed adjunctively in 11 (73%) of these. Retrievable IVC filters were placed in 6
subjects (38%). Median number of procedure days for PMT +/− CDTI was 2 (range: 1–4).
Outcomes
Safety and efficacy outcomes are summarized in Table 3. With regard to safety, there were
no peri-procedural major bleeding events and one symptomatic pulmonary embolism. As for
efficacy, technical success (grade II/III lysis) was achieved in 94% (95% confidence interval
[CI]: 70->99%) of cases. There were five acute local recurrences within one week (all of
which were successfully re-lysed), one sub-acute, and four late local recurrences. Late local
recurrences were restricted in all cases to patients with severe hypercoagulability, with or
without underlying stenotic venous lesions, as follows: asparaginase-induced multiple
thrombophilias (n=1); severe protein S deficiency with May-Thurner anomaly (n=1);
antiphospholipid antibody syndrome (APS, n=1); and APS with May-Thurner anomaly
(n=1). Using Society of Interventional Radiology outcomes reporting criteria [9; see also
Methods], overall early (<30 days) and late (>30 days; median follow-up duration: 14
months [range: 1–42 months]) rethrombosis rates were therefore 40% (95% CI: 20–64%)
and 27% (95% CI: 10–52%), respectively. Cumulative incidence of any PTS (physical
findings on the basic CEAP component or chronic pain findings on the Wong-Baker
component of the Manco-Johnson instrument) at 1–2 years was 80% (95% CI: 48–95%),
while that of. both physically and functionally significant PTS (abnormalities on both
components of the instrument) was 13% (95% CI: 0.1–49%).
Prognostic factors for PTS
The results of univariate analyses for prognostic factors with regard to therapeutic efficacy
are shown in Table 4. While no statistically significant associations were detected (and
while sample size per group was small), a tendency toward increased risk of physically and
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functionally significant PTS was observed among patients in whom: lag time from symptom
onset to lytic intervention exceeded ten days; stenotic venous anomalies were disclosed (all
of which were successfully stented); and PMT (rather than PPMT) was used. The latter
observation was accompanied by a tendency toward increased rates of locally recurrent
DVT for PMT in comparison to PPMT.
Discussion
The present findings provide prospective evidence that PMT/PPMT with/without adjunctive
CDTI can be used safely in children, targeting a subgroup of adolescents with DVT known
to be at high a priori risk for PTS. Peri-procedural symptomatic pulmonary embolism
occurred in only one patient and major bleeding was absent among 16 consecutively
enrolled cases in the cohort study. Despite acute locally recurrent DVT in 40%, 83% of
these were successfully re-lysed. While late recurrent DVT occurred in 27% overall, all
were in the setting of severe hypercoagulable states. Although signs and/or symptoms of
PTS were still observed in some patients even when PMT/PPMT was performed within 10
days of symptom onset, the rate of functionally significant PTS occurred in only 13% of
these high-risk patients. These findings identify PMT/PPMT with adjunctive CDTI as
worthy of further prospective study as an effective and potentially safer (vis-à-vis systemic
bleeding risk) alternative to systemic thrombolysis in children with occlusive proximal limb
DVT who have adverse prognostic biomarkers at acute presentation.
Several additional observations in this study are important, including use of retrievable IVC
filters and endovascular stents. Outcomes for the use of retrievable IVC filters in children
have rarely been reported previously. The present finding of non-retrievability in two of six
cases (33%) in which retrievable IVC filters were placed is consistent with a similar
observation in one of six cases in the single prospective pediatric series of IVC filter use
published to date [16]. In our series, non-retrievability was associated with accumulation of
organized thrombus at the site where the filter legs apposed the IVC wall. In one case, there
was a prolonged interval to filter retrieval (three months from time of placement). In the
other, retrieval was within a conventional timeframe (six weeks from placement), but the
patient’s course was complicated by prolonged, severe coagulation activation as multimodal
immunosuppressive and antithrombotic therapies were being escalated for the treatment of
thrombotic storm in APS. These cases highlight the importance of careful consideration of
risks and benefits of retrievable IVC filters in children, and the need for collaborative studies
to provide more extensive data on this issue in the context of a rare disease.
Our preliminary finding of a low risk of recurrent VTE following iliac vein stenting for
May-Thurner anomaly in children without sever underlyinig thrombophilia is supported by
the two prior series (both retrospective) in this area [17,18]. None of the patients ≤ 21 years
of age in these reports suffered recurrent VTE, at median follow-up durations of 11 and 18
months. Like our study, these prior series involved PMT/PPMT with/without CDTI prior to
stent placement. Our prospective series involved six cases of May-Thurner anomaly. Among
the five adolescents with May-Thurner anomaly in whom PMT/PPMT was performed
within six weeks of symptom onset, with a median follow-up duration of 10 months, locally
recurrent DVT developed in two subjects, both with severe underlying thrombophilia. In
another case, recurrent VTE consisted of a distant event (subclavian DVT at the site of
peripherally-inserted central catheter) unrelated to May-Thurner anomaly. Taken together,
these experiences suggest that, in a disorder for which risk of recurrent VTE historically
appears to be high, interventional thrombolysis with iliac vein stent placement may provide
an effective means of secondary VTE prevention. However, our sample size with May-
Thurner anomaly is small; as with the case of retrievable IVC filters, larger efforts are
needed to adequately investigate this issue.
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A recent systematic review of the literature revealed a weighted mean frequency of PTS in
children of nearly 25%, albeit with considerable variability across eligible studies [3].
Pediatric findings with the use of a standardized PTS scoring system (adapted from Villalta
scale) were first published in 2003 in a retrospective analysis by the Childhood
Thrombophilia Program at the Hospital for Sick Children [19]; this study reported a
prevalence of PTS of 63%. Prospective evidence using a pediatric PTS outcome measure,
the Manco-Johnson instrument (for which validation data were subsequently published [2]),
has indicated a cumulative incidence of PTS (as defined by physical or functional findings)
of 33% at 1–2 years among unselected children [11]. In addition, a cumulative incidence of
77% was observed at approximately 2 years using the Manco-Johnson instrument in a small
cohort of children with completely-occlusive lower limb DVT treated with standard
anticoagulation in whom plasma levels of factor VIII and D-dimer were acutely elevated [2].
In this latter group, the frequency of PTS characterized by both physical and functional
findings was 31%. The present finding of a cumulative incidence of physically and
functionally significant PTS of only 13% at 1–2 years in a cohort of children sharing these
adverse prognostic clinical and laboratory features indicates that PPMT deserves further
evaluation as a potential means for PTS risk-reduction in this high-risk stratum of pediatric
DVT.
The pathophysiology of PTS is thought to ultimately involve venous hypertension [20],
which, in turn, is believed to derive from venous valvular reflux and/or persistent thrombotic
veno-occlusion following DVT. The fact that PTS developed in several children in the
present cohort in whom patency was both achieved acutely following PPMT and maintained
long-term suggests that these patients may have irreversible valvular damage in the affected
limb at the time of presentation or ongoing vascular inflammation following successful lysis.
While plethysmography and other techniques of assessing venous valvular function were not
performed in this cohort study, it should be recognized that PTS has been shown to correlate
poorly with the presence of reflux by conventional methods [21]. As an alternative
pathophysiological explanation to reflux secondary to mechanical valve damage, it is
possible that valvular fibrosis and damage due to inflammation (whether systemic or
localized to the vasculature) may be sufficient to cause insufficiency in these cases. Indeed,
some evidence to date in adult DVT identifies elevated levels of interleukin-6 and D-dimer
as prognostic of PTS [22,23]; the latter was a key inclusion criterion for cases in this cohort,
based upon prior knowledge of prognostic factors for adverse outcomes of thrombosis in
children [11].
Findings from a recent meta-analysis of randomized controlled trials (RCTs) of additional
thrombolysis (systemic infusion or CDTI) versus standard anticoagulation alone revealed
that, although mortality and the risk of recurrent VTE are not reduced by thrombolysis, the
acute rate of complete patency is significantly increased (RR=4.14, 95% CI=1.22–14.01),
and the risk of PTS is decreased (RR=0.66, 95% CI=0.47–0.94) [24]. However, a slight but
statistically significant increase in acute major bleeding risk was ascribed to thrombolysis by
systemic infusion/CDTI [RR=1.73, 95% CI=1.04–2.88]. Furthermore, the findings for PTS
were based on only two RCTs in which this outcome was reported [25,26]. Recently (and
not included in the aforementioned Cochrane review), early outcomes from the CaVenT trial
indicate a significant risk reduction in chronic venous obstruction among adult patients with
acute proximal DVT treated by additional CDTI when compared to those who received
standard anticoagulation alone [27]. Evaluation for the primary endpoint of this trial, the rate
of PTS at two years, is ongoing.
A potential advantage of the PMT/PPMT approach is the reduction in total dose of
thrombolytic agent administered relative to thrombolysis by systemic infusion or CDTI,
with a consequent theoretical benefit of decreased bleeding risk. Furthermore, PMT/PPMT
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offers the advantage of minimizing systemic lytic exposure in particular, thereby presumably
decreasing systemic bleeding risks involving critical sites such as the central nervous
system. No RCTs of PMT/PPMT have been published, and prospective data on this lytic
intervention for DVT are limited to two adult studies focused upon CDTI, in which PMT/
PPMT was reported in a few cases each [28,29]. By comparison, nine retrospective studies
have been reported, totaling approximately 200 adult DVT patients treated by PMT/PPMT
with/without adjunctive CDTI [30–37]. However, published experience with a regimen of
PMT/PPMT followed by adjunctive CDTI is limited to three retrospective studies in adults,
in which the number of patients receiving this regimen ranged between eight and 20
[30,33,34].
With regard to safety of PMT/PPMT with/without CDTI, only six cases of acute major
bleeding and zero cases of acute symptomatic PE were reported among the nine
retrospective studies, out of 172 and 107 patients, respectively, in whom this outcome was
assessed. These low rates of peri-procedural hemorrhage and PE are consistent with our
prospective findings in the present cohort. As for potential efficacy of PMT/PPMT, acute
patency rates were high across the nine retrospective studies. However, long-term patency
was only reported by Lin and colleagues [31], who determined a rate of 65%. No cases of
acute recurrent DVT were reported among a cumulative total of 62 subjects in the
retrospective studies wherein this outcome was assessed. Our findings of a higher rate of
early local recurrent VTE in this prospective cohort could be explained by one or more of
the following possibilities: (1) the risk of acute re-occlusion may be higher in children than
adults; (2) observation biases may have led to under-reporting in the retrospective studies;
(3) children in the present study were generally more prothrombotic than the adults reported
in prior series. Given the latter possibility, and the low bleeding risks observed here, the
present authors currently advocate for more aggressive peri-procedural anticoagulation than
employed in these subjects. With regard to PTS, the findings reported here are the first
among prospective or retrospective studies of PMT/PPMT in children or adults. Future
analyses of PMT/PPMT must build upon this work, emphasizing PTS as a key outcome, and
using validated measures.
Principal strengths of the present work include: the prospective inception cohort design;
comprehensive clinical and laboratory evaluation for predisposing conditions (including
venous stenoses and thrombophilia states); standardization of peri-procedural and extended
anti-coagulant regimens; and PTS outcomes measurement, using a standardized instrument
for which data on validity have been published in children. The principal limitations of the
present observational study are its non-randomized design and its relatively small size. As in
other non-randomized studies, selection biases may exist (e.g., clinical determination of
PMT vs. PPMT and use/non-use of CDTI). Additionally, in spite of the fact that this is the
largest pediatric series on PMT/PPMT, and similar in size to previous adult studies of PMT/
PPMT in which adjunctive CDTI was frequently employed, it must be emphasized that our
outcome estimates (e.g.: acute locally recurrent DVT, PE, and major hemorrhage; late
recurrent VTE; PTS) may be imprecise given the size of our study population. In particular,
PTS may develop over time, and may be underestimated here; yet, in prior work by the
authors, for all children found to be affected at 2 years, PTS had been evident at 1 year post-
event [2]. Given the study limitations of sample size, the tendencies observed for putative
prognostic indicators of long-term patency and PTS must also be considered speculative.
Therefore, larger prospective studies are required in order to confirm the safety of PMT/
PPMT with adjunctive CDTI, evaluate its efficacy for PTS risk reduction, and define
additional prognostic factors in this young patient population.
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Flow chart of subject selection from the cohort study population, based upon clinical and
laboratory characteristics of interest for heightened a priori risk of PTS.
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Observed relative contraindications to local thrombolytic invervention. These relative
contraindications were adapted from absolute and relative contraindications to systemic
thrombolysis. Contraindications were considered relative based upon the possibility of
systemic exposure to thrombolytic agent in small amounts during PMT, or in large amounts
during CDTI once patency achieved. No patients were excluded for contraindications.
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Summary of clinical protocol for PMT/PPMT.
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